24
Participants
Start Date
June 18, 2024
Primary Completion Date
October 15, 2025
Study Completion Date
February 14, 2026
AMT-676
Participants will receive AMT-676 administered intravenously. Participants will be observed for first instance of dose limiting toxicities (DLT).
NOT_YET_RECRUITING
John Hopkins Sidney Kimmel Comprehensive Cancer Center, Philadelphia
NOT_YET_RECRUITING
Carolina Biooncology Institute, Huntersville
NOT_YET_RECRUITING
Shanghai East Hospital, Shanghai
NOT_YET_RECRUITING
Sir Run Run Shaw Hospital, Hangzhou
NOT_YET_RECRUITING
Fujian Provincial Cancer Hospital, Fuzhou
NOT_YET_RECRUITING
Sun Yat-sen University Cancer Center, Guangzhou
NOT_YET_RECRUITING
Sichuan Provincial People's Hospital, Chengdu
NOT_YET_RECRUITING
South Texas Accelerated Research Therapeutics (start) San Antonio, San Antonio
RECRUITING
SCIENTIA Clinical Research Ltd, Randwick
RECRUITING
Macquarie University Hospital, Macquarie
RECRUITING
Gallipoli Medical Research Foundation, Greenslopes
RECRUITING
Cabrini Hospital, Melbourne
RECRUITING
Linear Research, Nedlands
Lead Sponsor
Multitude Therapeutics Inc.
INDUSTRY